Material Event Form 8 K

Item 8.01 Other Events.

As previously disclosed in Entero Therapeutics, Inc.'s (the "Company") Current Report on Form 8-K filed with the SEC on August 7, 2024, on August 2, 2024, the Company's subsidiary, ImmunogenX, LLC ("ImmunogenX"), received a Notice of Default (the "Notice") relating to that certain Credit Agreement, dated as of October 3, 2022 (as amended, modified, supplemented or restated from time to time, the "Credit Agreement") by and among Mattress Liquidators, Inc. (the "Lender") and ImmunogenX, Inc., the predecessor entity of ImmunogenX. The Notice informed ImmunogenX that one or more events of default under the Credit Agreement were existing and continuing. Such outstanding Events of Default alleged by Lender included ImmunogenX suffering an adverse change in its financial condition which would reasonably be expected to have a Material Adverse Effect (as defined in the Credit Agreement) (the "MAE Default"). The Notice additionally indicated that, as a result of the MAE Default, pursuant to the terms of Section 8.3 of the Credit Agreement, (a) the outstanding principal balance of the loan made under the Credit Agreement, all interest and fees related thereto, and all other outstanding obligations were accelerated and declared immediately due and payable, and that Lender demanded immediate payment of all obligations, and (b) Lender increased the effective interest rate to the Default Rate (as defined in the Credit Agreement).

On August 29, 2024, after discussions with Lender, ImmunogenX received a letter (the "Letter") from Lender informing ImmunogenX that at this time, Lender is suspending the MAE Default. The Letter additionally provided that Lender's suspension of the MAE Default is not, and shall not be construed as, a waiver of the MAE Default and Lender expressly reserves all rights with respect to its enforcement of the MAE Default.